Clinical Evaluation and Outcome in Heart Failure Patients Receiving Chemotherapy with Different Anti-Cancer Agents
Main finding · ReadmissionResult — go to the resultOdds ratio 1.26 95% CI 1.17–1.36Authors' conclusion
Medical providers need to monitor and follow-up patients with HF, depending on the characteristics of the anti-cancer agents and types of cancer.
Study context
- Population
- Patients hospitalized for heart failure (HF) between April 2012 and March 2021, with or without chemotherapypatients hospitalized for HF, matched analysis of 11,532 patients
- Participants
- 1,328,113 patients
- Exposure
- Patients with HF who received chemotherapy compared with those of a matched cohort with HF who did not receive chemotherapy
- Outcome
- Readmission
Methodological detailsbased on the Diagnosis Procedure Combination (DPC) database of the Japanese Registry of All Cardiac and Vascular Diseases (JROAD), real-world HF data
- Based on the Diagnosis Procedure Combination (DPC) database of the Japanese Registry of All Cardiac and Vascular Diseases (JROAD)
- Real-world HF data
Main finding
As reported in the abstract
Odds ratio
1.26
95% CI 1.17–1.36
P < 0.01
Patients with chemotherapyvs patients without chemotherapy
OR 1.26 (95% CI 1.17–1.36); P < 0.01
Observational data: associations, not effects.
Further findings
Readmission by anti-cancer agent
| OR (95% CI) | ||
|---|---|---|
| EGFR-TKIsHigher risk of readmission | 1.69 (1.39–2.07) | |
| TaxaneHigher risk of readmission | 2.95 (2.11–4.12) | |
| AnthracyclinesHigher risk of readmission | 1.86 (1.19–2.90) | |
| Fluorouracil agentsHigher risk of readmission | 1.65 (1.18–2.30) | |
| 0.20.5125Odds ratio (log scale) |
Cancer types
- Colon, lung, breast and prostate cancers accounted for
- >60% of all cancer types
Original publication
Clinical Evaluation and Outcome in Heart Failure Patients Receiving Chemotherapy with Different Anti-Cancer Agents. ESC Heart Fail. Published 13 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →